Acute toxicity study of a nonsteroidal anti-inflammatory drug for dogs based on celecoxib

The article presents the results of the study of acute toxicity of the veterinary drug “Celecoxib” with the active substance celecoxib on white rats. The drug “Celecoxib” is a solution for injection. 1 ml of the drug contains celecoxib – 100 mg and the excipient – pyralidone-2. The veterinary drug is prescribed to dogs to reduce inflammation and pain in inflammatory and pain syndromes of various origins, such as acute and chronic diseases of the musculoskeletal system (fractures, injuries, sprains of ligaments and tendons, osteoarthritis, chronic degenerative joint diseases), as well as as an analgesic and anti-inflammatory drug in complex therapy. According to the results of determining the acute toxicity parameters of the drug “Celecixib” (solution for injection), in the case of a single intragastric administration, the LD50 for male rats is 7837.85 ± 686.05 mg/kg of body weight, which allows us to attribute it to class V – practically non-toxic substances (LD50 5001–15000 mg/kg), and to class IV – low-hazard substances (LD50 > 5000 mg/kg) in terms of toxicity. According to the results of determining the acute toxicity parameters of the drug “Celecoxib” (solution for injection), in the case of a single subcutaneous injection, the LD50 for female rats is 40903.49 ± 6259.52 mg/kg body weight, and for male mice – 35448.61 ± 5618.78 mg/kg body weight, which allows us to classify the drug as class VI – relatively harmless substances (LD50Subcut >4500 mg/kg body weight). Further studies will be the next stage of pre-registration tests aimed at studying the toxicity of the drug “Celecoxib”. It will be important to assess the long-term effect of celecoxib on the body of dogs with prolonged use. This will allow us to understand whether the metabolites of the drug accumulate in organs and tissues and how they affect the liver, kidneys and other systems. These studies are mandatory materials in the section “Safety and Residue Studies” of the dossier for this medicinal product.